Dose‐related neuroprotective effects of chronic nicotine in 6‐hydroxydopamine treated rats, and loss of neuroprotection in α4 nicotinic receptor subunit knockout mice
Open accessAbstract
The present study examined the effect of a range of doses of chronic nicotine (0.75, 1.5, 3.0 and 30.0 mg kg−1 day−1, s.c., 14 days) upon striatal dopaminergic nerve terminal survival following 6‐hydroxydopamine (6‐OHDA; 10 μg intrastriatal unilaterally) in rats; and the effects of acute nicotine (1 mg kg−1, s.c.) pretreatment upon striatal neurodegeneration induced by methamphetamine (5 mg kg−1, i.p., three doses at 2 h intervals) in wild‐type and α4 nicotinic receptor (nAChR) subunit knockout mice. In both models of Parkinsonian‐like damage, loss of striatal dopaminergic nerve terminals was assessed by [3 H]‐mazindol autoradiography. In rats, chronic nicotine infusion delivered by osmotic minipump implanted subcutaneously 7 days prior to intrastriatal 6‐OHDA injection produced significant and dose‐related protection against 6‐OHDA‐induced neurodegeneration. Low (0.75 and 1.5 mg kg−1 day−1) but not high (3.0 and 30.0 mg kg−1 day−1) nicotine doses significantly inhibited 6‐OHDA‐induced degeneration. In wild‐type mice, acute nicotine treatment produced significant inhibition of methamphetamine‐induced neurodegeneration. In α4 nAChR subunit knockout mice, acute nicotine treatment failed to inhibit methamphetamine‐induced neurodegeneration. Nicotine is capable of protecting dopaminergic neurons against Parkinsonian‐like neurodegeneration in vivo. In rats, this neuroprotective effect is critically dependent upon nicotine dose and is consistent with the activation of nAChRs, as high, desensitizing doses of nicotine fail to be neuroprotective. Further, neuroprotection is absent in α4 nAChR subunit knockout mice. The current results therefore suggest that activation of α4 subunit containing nAChRs constitutes a major component of the neuroprotective effect of nicotine upon Parkinsonian‐like damage in vivo. British Journal of Pharmacology (2001) 132, 1650–1656; doi:10.1038/sj.bjp.0703989
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Nicotine protects rodent DA neurons against toxin-induced cell loss.
“Nicotine protects rodent DA neurons agonist toxin-induced cell loss (21–24), but these neuroprotective effects are absent in α4 nAChR knockout (KO) mice (22).”
From Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery (2009) · cites this paper as [22]
The neuroprotective effects of nicotine against toxin-induced DA neuron loss are absent in α4 nAChR knockout mice.
“Nicotine protects rodent DA neurons agonist toxin-induced cell loss (21–24), but these neuroprotective effects are absent in α4 nAChR knockout (KO) mice (22).”
From Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery (2009) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Rat Brain in Stereotaxic Coordinates
Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585 · see citing works
Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,612 · see citing works
ETIOLOGY AND PATHOGENESIS OF PARKINSON'S DISEASE
Olanow, C. W., & Tatton, W. G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.123 · Cited by 1,394 · see citing works
Presynaptic nicotinic ACh receptors
Wonnacott, S. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10073-4 · Cited by 1,308 · see citing works
Sauer, H., & Oertel, W. H. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90605-x · Cited by 807 · see citing works
Gerlach, M., & Riederer, P. F. (1996) · Journal of Neural Transmission · doi:10.1007/bf01291788 · Cited by 496 · see citing works
Role for Excitatory Amino Acids in Methamphetamine-Induced Nigrostriatal Dopaminergic Toxicity
Sonsalla, P. K., Nicklas, W. J., & Heikkila, R. E. (1989) · Science · doi:10.1126/science.2563176 · Cited by 483 · see citing works
Przedbroski, S., Leviver, M., Jiang, H., Ferreira, M., Jackson-Lewis, V. R., Donaldson, D. M., & Togasaki, D. M. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00066-r · Cited by 453 · see citing works
Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons
Lotharius, J., Dugan, L. L., & O’Malley, K. L. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-04-01284.1999 · Cited by 403 · see citing works
Cigarette smoking and protection from Parkinson's disease
Morens, D. M., Grandinetti, A., REED, D. M., White, L. R., & Ross, G. W. (1995) · Neurology · doi:10.1212/wnl.45.6.1041 · Cited by 368 · see citing works
The paradox of nicotinic acetylcholine receptor upregulation by nicotine
Wonnacott, S. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90242-z · Cited by 357 · see citing works
Grady, S., Marks, M. J., Wonnacott, S., & Collins, A. C. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08322.x · Cited by 350 · see citing works
Brain nicotinic receptors: structure and regulation, role in learning and reinforcement
Changeux, J.-P., Bertrand, D., Corringer, P.-J., Dehaene, S., Edelstein, S., Léna, C., Le Novère, N., Marubio, L., Picciotto, M., & Zoli, M. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(97)00040-4 · Cited by 322 · see citing works
Cigarette smoking and Parkinson's disease
Baron, J. A. (1986) · Neurology · doi:10.1212/wnl.36.11.1490 · Cited by 295 · see citing works
Marshall, D. L., Redfern, P. H., & Wonnacott, S. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68041511.x · Cited by 284 · see citing works
[3H]mazindol binding associated with neuronal dopamine and norepinephrine uptake sites.
Javitch, J. A., Blaustein, R. O., & Snyder, S. H. (1984) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14974-2 · Cited by 283 · see citing works
Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states
Lévy, R., Hazrati, L., Herrero, M. T., Vila, M., Hassani, O.-K., Mouroux, M., Ruberg, M., Asensi, H., Agid, Y., Féger, J., et al. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00409-5 · Cited by 270 · see citing works
Clarke, P. B. S., & Reuben, M. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15232.x · Cited by 262 · see citing works
Lee, C. S., Sauer, H., & Björklund, A. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00571-4 · Cited by 252 · see citing works
Javitch, J. A., Strittmatter, S. M., & Snyder, S. H. (1985) · Journal of Neuroscience · doi:10.1523/jneurosci.05-06-01513.1985 · Cited by 244 · see citing works
Akaike, A., Tamura, Y., Yokota, T., Shimohama, S., & Kimura, J. (1994) · Brain Research · doi:10.1016/0006-8993(94)91678-0 · Cited by 240 · see citing works
Maggio, R., Riva, M. A., Vaglini, F., Fornai, F., Molteni, R., Armogida, M., Racagni, G., & Corsini, G. U. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71062439.x · Cited by 218 · see citing works
Ross, S. A., Wong, J. Y. F., Clifford, J. J., Kinsella, A., Massalas, J. S., Horne, M. K., Scheffer, I. E., Kola, I., Waddington, J. L., Berkovic, S. F., et al. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06431.2000 · Cited by 204 · see citing works
Self-citationNeuronal nicotinic receptors : pharmacology and therapeutic opportunities
Arnerić, S. P., & Brioni, J. D. (1999) · Wiley-Liss eBooks · Cited by 202 · see citing works
Stimulation of α4β2 nicotinic acetylcholine receptors inhibits β-amyloid toxicity
Kihara, T., Shimohama, S., Urushitani, M., Sawada, H., Kimura, J., Kume, T., Maeda, T., & AKAIKE, A. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00138-3 · Cited by 193 · see citing works
Kaneko, S., Maeda, T., Kume, T., Kochiyama, H., Akaike, A., Shimohama, S., & Kimura, J. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00556-8 · Cited by 193 · see citing works
Sonsalla, P. K., Riordan, D. E., & Heikkila, R. E. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22956-1 · Cited by 184 · see citing works
Sharples, C. G. V., Kaiser, S., Soliakov, L. S., Marks, M. J., Collins, A. C., Washburn, M. S., Wright, E., Spencer, J. A., Gallagher, T., Whiteaker, P., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-08-02783.2000 · Cited by 164 · see citing works
Berger, K., Przedborski, S., & Cadet, J. L. (1991) · Brain Research Bulletin · doi:10.1016/0361-9230(91)90242-c · Cited by 147 · see citing works
Janson, A. M., & Møller, A. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90039-i · Cited by 128 · see citing works
Grady, S. R., Marks, M. J., & Collins, A. C. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62041390.x · Cited by 126 · see citing works
Dose‐Response Relationship for Nicotine‐Induced Up‐Regulation of Rat Brain Nicotinic Receptors
Rowell, P. P., & Li, M. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68051982.x · Cited by 124 · see citing works
Janson, A. M., Fuxé, K., Agnati, L. F., Kitayama, I. T., Härfstrand, A., Andersson, K., & Goldstein, M. (1988) · Brain Research · doi:10.1016/0006-8993(88)90092-3 · Cited by 114 · see citing works
In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418
Donnelly‐Roberts, D. L., Xue, I. C., Arnerić, S. P., & Sullivan, J. P. (1996) · Brain Research · doi:10.1016/0006-8993(96)00063-7 · Cited by 103 · see citing works
Regional variation in the effects of nicotine on catecholamine overflow in rat brain
Benwell, M. E. M., & Balfour, D. J. K. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)00101-5 · Cited by 89 · see citing works
Maggio, R., Riva, M. A., Vaglini, F., Fornai, F., Racagni, G., & Corsini, G. U. (1997) · Journal of Neural Transmission · doi:10.1007/bf01273324 · Cited by 86 · see citing works
Janson, A. M., Fuxé, K., & Goldstein, M. (1992) · Journal of Molecular Medicine · doi:10.1007/bf00184656 · Cited by 84 · see citing works
Ferger, B., Spratt, C., Earl, C. D., Teismann, P., Oertel, W. H., & Kuschinsky, K. (1998) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00005264 · Cited by 78 · see citing works
Fuxé, K., Jansson, A. M., Jansson, A., Andersson, K., Eneroth, P. H. E., & Agnati, L. F. (1990) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00169727 · Cited by 70 · see citing works
Locomotor activation and dopamine release produced by nicotine and isoarecolone in rats
Whiteaker, P., Garcha, H. S., Wonnacott, S., & Stolerman, I. P. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb16417.x · Cited by 66 · see citing works
JANSON, A. M., FUXE, K., SUNDSTRÖM, E., AGNATI, L. F., & GOLDSTEIN, M. (1988) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1988.tb08372.x · Cited by 56 · see citing works
Janson, A. M., Meana, J. J., Goiny, M., & Herrera‐Marschitz, M. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90515-u · Cited by 39 · see citing works
Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists.
Hadjiconstantinou, M., Hubble, J. P., Wemlinger, T. A., & Neff, N. H. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22396-5 · Cited by 37 · see citing works
Elliott, K. J., Jones, J. M., Sacaan, A. I., Lloyd, G. K., & Corey-Naeve, J. (1998) · Journal of Molecular Neuroscience · doi:10.1007/bf02761778 · Cited by 34 · see citing works
Reuben, M., Boye, S., & Clarke, P. B. S. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00004-2 · Cited by 33 · see citing works
Blum, M., Wu, G., Mudò, G., Belluardo, N., Andersson, K., Agnati, L. F., & Fuxé, K. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00364-o · Cited by 30 · see citing works
Janson, A. M., Hedlund, P. B., Fuxé, K., & von Euler, G. (1994) · Brain Research · doi:10.1016/0006-8993(94)91593-8 · Cited by 29 · see citing works
Semba, J., Miyoshi, R., & Kito, S. (1996) · Brain Research · doi:10.1016/0006-8993(96)00926-2 · Cited by 26 · see citing works
Grenhoff, J., Janson, A. M., Svensson, T. H., & Fuxé, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)90646-d · Cited by 25 · see citing works
Owman, C., Fuxé, K., Janson, A. M., & Kåhrström, J. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90092-x · Cited by 24 · see citing works
Flagged first, then by citations
1 of the 51 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Arneric, S.P. & Brioni, J.D. pp. 127 ± 139, Wiley-Liss.
Cited by
Sorted by citations
Neuronal nicotinic receptors: from structure to pathology
Gotti, C., & Clementi, F. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.09.006 · Cited by 970 · see citing works
Neurotoxin-based models of Parkinson's disease
Bové, J., & Perier, C. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.10.057 · Cited by 508 · see citing works
Smoking, nicotine and Parkinson's disease
Quik, M. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.06.008 · Cited by 323 · see citing works
Buckingham, S. D., Jones, A. K., Brown, L. A., & Sattelle, D. B. (2009) · Pharmacological Reviews · doi:10.1124/pr.108.000562 · Cited by 307 · see citing works
Nicotinic acetylcholine receptors as targets for antidepressants
Shytle, R. D., Silver, A. A., Lukas, R. J., Newman, M. B., Sheehan, D. V., & Sanberg, P. R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001035 · Cited by 279 · see citing works
Nashmi, R., Xiao, C., Deshpande, P., McKinney, S., Grady, S. R., Whiteaker, P., Huang, Q., McClure-Begley, T., Lindstrom, J. M., Labarca, C., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2199-07.2007 · Cited by 274 · see citing works
The ongoing pursuit of neuroprotective therapies in Parkinson disease
Athauda, D. S., & Foltynie, T. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.226 · Cited by 267 · see citing works
Monoamine oxidase and cigarette smoking
Fowler, J. S., Logan, J., Wang, G.-J., & Volkow, N. D. (2003) · NeuroToxicology · doi:10.1016/s0161-813x(02)00109-2 · Cited by 251 · see citing works
Nicotine as a potential neuroprotective agent for Parkinson's disease
Quik, M., Perez, X. A., & Bordia, T. (2012) · Movement Disorders · doi:10.1002/mds.25028 · Cited by 242 · see citing works
Neuroprotective Strategies in Parkinson???s Disease
Mandel, S. A., Grünblatt, E., Riederer, P. F., Gerlach, M., Levites, Y., & Youdim, M. B. H. (2003) · CNS Drugs · doi:10.2165/00023210-200317100-00004 · Cited by 238 · see citing works
Picciotto, M. R., Caldarone, B. J., Brunzell, D. H., Zachariou, V., Stevens, T. R., & King, S. L. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00161-9 · Cited by 221 · see citing works
Smoking, nicotine and neuropsychiatric disorders
Döme, P., Lazáry, J., Kalapos, M. P., & Rihmer, Z. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.07.013 · Cited by 215 · see citing works
Bauman, M. L. (2006) · Johns Hopkins University Press eBooks · doi:10.1353/book.3225 · Cited by 215 · see citing works
Picciotto, M. R. (2007) · Frontiers in bioscience · doi:10.2741/2695 · Cited by 212 · see citing works
Nicotinic receptors in aging and dementia
Picciotto, M. R., & Zoli, M. (2002) · Journal of Neurobiology · doi:10.1002/neu.10102 · Cited by 207 · see citing works
Functional brain imaging of tobacco use and dependence
BRODY, A. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.04.012 · Cited by 207 · see citing works
α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson’s Disease
Quik, M., & Wonnacott, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003269 · Cited by 194 · see citing works
Takada‐Takatori, Y., Kume, T., Sugimoto, M., Katsuki, H., Sugimoto, H., & Akaike, A. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.04.007 · Cited by 188 · see citing works
Desensitized nicotinic receptors in brain
Wang, H., & Sun, X. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.09.003 · Cited by 175 · see citing works
Shaw, S., Bencherif, M., & Marrero, M. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204610200 · Cited by 172 · see citing works
Lester, H. A., Xiao, C., Srinivasan, R., Son, C. D., Miwa, J., Pantoja, R., Banghart, M. R., Dougherty, D. A., Goate, A. M., & Wang, J. C. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9090-7 · Cited by 163 · see citing works
Caffeinated clues and the promise of adenosine A2Aantagonists in PD
Schwarzschild, M. A., Chen, J., & Ascherio, A. (2002) · Neurology · doi:10.1212/wnl.58.8.1154 · Cited by 161 · see citing works
Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms
Mudò, G., Belluardo, N., & Fuxé, K. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0561-z · Cited by 156 · see citing works
Nicotine and Parkinson's disease: implications for therapy
Quik, M., O'Leary, K., & Tanner, C. M. (2008) · Movement Disorders · doi:10.1002/mds.21900 · Cited by 154 · see citing works
Neuroprotective effect of nicotine on dopaminergic neurons by anti‐inflammatory action
Park, H.-J., Lee, P. H., Ahn, Y. W., Choi, Y. J., Lee, G., Lee, D., Chung, E. S., & Jin, B. K. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05636.x · Cited by 153 · see citing works
Morales, A. M., Lee, B., Hellemann, G., O’Neill, J., & London, E. D. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.02.017 · Cited by 142 · see citing works
Chronic oral nicotine treatment protects against striatal degeneration in MPTP‐treated primates
Quik, M., Parameswaran, N., McCallum, S. E., Bordia, T., Bao, S., McCormack, A. L., Kim, A., Tyndale, R. F., Langston, J. W., & Monte, D. A. D. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04078.x · Cited by 137 · see citing works
Soto‐Otero, R., Méndez‐Álvarez, E., Ameijeiras, Á. H., López-Real, A. M., & Labandeira-García, J. L. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01070-5 · Cited by 137 · see citing works
Current Evidence for Neuroprotective Effects of Nicotine and Caffeine Against Parkinson??s Disease
Ross, G. W., & Petrovitch, H. (2001) · Drugs & Aging · doi:10.2165/00002512-200118110-00001 · Cited by 137 · see citing works
Multiple roles for nicotine in Parkinson's disease
Quik, M., Huang, L. Z., Parameswaran, N., Bordia, T., Campos, C., & Perez, X. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.003 · Cited by 134 · see citing works
Cholinergic Modulation of Glial Function During Aging and Chronic Neuroinflammation
Gamage, R. V., Wagnon, I. M., Rossetti, I., Childs, R., Niedermayer, G., Chesworth, R., & Gyengési, E. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.577912 · Cited by 133 · see citing works
Nicotine and inflammatory neurological disorders
Piao, W.-H., Campagnolo, D. I., Dayao, C. S., Lukas, R. J., Wu, J., & Shi, F. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.67 · Cited by 131 · see citing works
Striatal α6* Nicotinic Acetylcholine Receptors: Potential Targets for Parkinson’s Disease Therapy
Quik, M., & McIntosh, J. M. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.094375 · Cited by 127 · see citing works
Alpha7 nicotinic receptors as therapeutic targets for Parkinson’s disease
Quik, M., Zhang, D., McGregor, M., & Bordia, T. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.06.014 · Cited by 113 · see citing works
Srivareerat, M., Tran, T. T., Salim, S., Aleisa, A. M., & Alkadhi, K. A. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.015 · Cited by 121 · see citing works
Stevens, T. R., Krueger, S. R., Fitzsimonds, R. M., & Picciotto, M. R. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-31-10093.2003 · Cited by 119 · see citing works
Xiao, C., Nashmi, R., McKinney, S. L., Cai, H., McIntosh, J. M., & Lester, H. A. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.2939-09.2009 · Cited by 115 · see citing works
Nicotinic Receptors in Neurodegeneration
Posadas, I., López‐Hernández, B., & Ceña, V. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030005 · Cited by 113 · see citing works
Nicotinic receptors as CNS targets for Parkinson's disease
Quik, M., Bordia, T., & O’Leary, K. T. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.015 · Cited by 116 · see citing works
Lai, A., Parameswaran, N., Khwaja, M., Whiteaker, P., Lindstrom, J. M., Fan, H., McIntosh, J. M., Grady, S. R., & Quik, M. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006429 · Cited by 112 · see citing works
Laudenbach, V., Medja, F., Zoli, M., Rossi, F., Evrard, P., Changeux, J., & Gressèns, P. (2002) · The FASEB Journal · doi:10.1096/fj.01-0532fje · Cited by 103 · see citing works
Huang, L. Z., Parameswaran, N., Bordia, T., McIntosh, J. M., & Quik, M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06011.x · Cited by 94 · see citing works
Nicotine neuroprotection against nigrostriatal damage: importance of the animal model
Quik, M., O’Neill, M. J., & Perez, X. A. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.03.001 · Cited by 93 · see citing works
In vivo Brain Imaging of Human Exposure to Nicotine and Tobacco
Sharma, A., & Brody, A. L. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-69248-5_6 · Cited by 88 · see citing works
Champtiaux, N., & Changeux, J. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007023339247 · Cited by 88 · see citing works
Alcohol consumption and the incidence of Parkinson's disease
Hernán, M. Á., Chen, H., Schwarzschild, M. A., & Ascherio, A. (2003) · Annals of Neurology · doi:10.1002/ana.10611 · Cited by 87 · see citing works
Pogocki, D., Ruman, T., Danilczuk, M., Danilczuk, M., Celuch, M., & Wałajtys-Rode, E. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.02.038 · Cited by 85 · see citing works
Eyerman, D. J., & Yamamoto, B. K. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.072264 · Cited by 85 · see citing works
Quik, M., Sum, J., Whiteaker, P., McCallum, S. E., Marks, M. J., Musachio, J. L., McIntosh, J. M., Collins, A. C., & Grady, S. R. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.5.1169 · Cited by 83 · see citing works
Linking Smoking, Coffee, Urate, and Parkinson’s Disease – A Role for Gut Microbiota?
Scheperjans, F., Pekkonen, E., Kaakkola, S., & Auvinen, P. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-150557 · Cited by 83 · see citing works
Mudò, G., Belluardo, N., Mauro, A., & Fuxé, K. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.12.012 · Cited by 83 · see citing works
Janhunen, S. K., & Ahtee, L. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2006.09.008 · Cited by 81 · see citing works
Maskell, P., Spéder, P., Newberry, N. R., & Bermúdez, I. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705559 · Cited by 80 · see citing works
Functional Diversity of Ventral Midbrain Dopamine and GABAergic Neurons
Korotkova, T. M., Ponomarenko, A. A., Brown, R. E., & Haas, H. L. (2004) · Molecular Neurobiology · doi:10.1385/mn:29:3:243 · Cited by 79 · see citing works
Tariq, M., Khan, H. A., Elfaki, I., Deeb, S. A., & Moutaery, K. A. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.06.024 · Cited by 76 · see citing works
Quik, M., Chen, L., Parameswaran, N., Xie, X., Langston, J. W., & McCallum, S. E. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0215-06.2006 · Cited by 77 · see citing works
Hormetic approaches to the treatment of Parkinson's disease: Perspectives and possibilities
Calabrese, V., Santoro, A., Salinaro, A. T., Modafferi, S., Scuto, M. C., Albouchi, F., Monti, D., Giordano, J., Zappia, M., Franceschi, C., et al. (2018) · Journal of Neuroscience Research · doi:10.1002/jnr.24244 · Cited by 76 · see citing works
Nicotine and neurodegeneration in ageing
Zanardi, A., Leo, G., Biagini, G., & Zoli, M. (2002) · Toxicology Letters · doi:10.1016/s0378-4274(01)00502-1 · Cited by 70 · see citing works
Taveira, M., Sousa, C., Valentão, P., Ferreres, F., Teixeira, J. P., & Andrade, P. B. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.12.013 · Cited by 69 · see citing works
Neuronal nicotinic receptors: insights gained from gene knockout an knocking mutant mice
Drago, J., McColl, C. D., Horne, M. K., Finkelstein, D. I., & Ross, S. A. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-2259-9 · Cited by 68 · see citing works
Self-citationPharmacological chaperoning of nAChRs: A therapeutic target for Parkinson's disease
Srinivasan, R., Henderson, B. J., Lester, H. A., & Richards, C. I. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.02.005 · Cited by 67 · see citing works
Bordia, T., McGregor, M. M., Papke, R. L., Decker, M. W., McIntosh, J. M., & Quik, M. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.09.015 · Cited by 67 · see citing works
Srinivasan, R., Henley, B. M., Henderson, B. J., Indersmitten, T., Cohen, B. N., Kim, C. H., McKinney, S. L., Deshpande, P., Xiao, C., & Lester, H. A. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.2126-15.2016 · Cited by 61 · see citing works
Nicotine and Nicotinic Receptor Drugs
Quik, M., Bordia, T., Zhang, D., & Perez, X. A. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.07.005 · Cited by 66 · see citing works
A reliable model of intravenous MDMA self-administration in naïve mice
Trigo, J. M., Panayi, F., Sòria, G., Maldonado, R. J., & Robledo, P. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0229-7 · Cited by 66 · see citing works
Kume, T., Sugimoto, M., Takada, Y., Yamaguchi, T., Yonezawa, A., Katsuki, H., Sugimoto, H., & Akaike, A. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.10.028 · Cited by 62 · see citing works
Protective effect of acetyl‐ l ‐carnitine on the apoptotic pathway of peripheral neuropathy
Mannelli, L. D. C., Ghelardini, C., Calvani, M., Nicolai, R., Mosconi, L., Vivoli, E., Pacini, A., & Bartolini, A. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05722.x · Cited by 62 · see citing works
A prospective study of alcoholism and the risk of Parkinson?s disease
Hernán, M. Á., Logroscino, G., & guez, L. A. G. A. R. (2004) · Journal of Neurology · doi:10.1007/s00415-004-1705-4 · Cited by 58 · see citing works
Study of the behavioural responses related to the potential addictive properties of MDMA in mice
Robledo, P., Balerio, G. N., Berrendero, F., & Maldonado, R. J. (2004) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-003-0862-9 · Cited by 56 · see citing works
Oxidative Modification and Its Implications for the Neurodegeneration of Parkinson’s Disease
Zhao, J., Yu, S., Zheng, Y., Yang, H., & Zhang, J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9743-3 · Cited by 55 · see citing works
Khwaja, M., McCormack, A., McIntosh, J. M., Di Monte, D. A., & Quik, M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04177.x · Cited by 54 · see citing works
Champtiaux, N., & Changeux, J. (2004) · Progress in brain research · doi:10.1016/s0079-6123(03)45016-4 · Cited by 53 · see citing works
Hosur, V., & Loring, R. H. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.066381 · Cited by 52 · see citing works
Cao, J., Tang, Y., Li, Y., Gao, K., Shi, X., & Li, Z. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00005 · Cited by 52 · see citing works
Targeting the cholinergic system in Parkinson’s disease
Liu, C. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0380-z · Cited by 53 · see citing works
Karadsheh, M. S., Shah, M. S., Tang, X., Macdonald, R. L., & Stitzel, J. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02801.x · Cited by 52 · see citing works
Bao, J., Lei, D., Du, Y., Ohlemiller, K. K., Beaudet, A. L., & Role, L. W. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.5277-04.2005 · Cited by 51 · see citing works
Singh, S., Singh, K., Patel, D. K., Singh, C., Nath, C., Singh, V. K., Singh, R. K., & Singh, M. P. (2009) · Rejuvenation Research · doi:10.1089/rej.2009.0850 · Cited by 47 · see citing works
Stimulation of nicotinic acetylcholine receptors protects motor neurons
Nakamizo, T., Kawamata, J., Yamashita, H., Kanki, R., Kihara, T., Sawada, H., Akaike, A., & Shimohama, S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.115 · Cited by 47 · see citing works
Protective effects of nicotine on ethanol-induced toxicity in cultured cerebellar granule cells
Tizabi, Y., Al-Namaeh, M., Manaye, K. F., & Taylor, R. E. (2003) · Neurotoxicity Research · doi:10.1007/bf03033151 · Cited by 47 · see citing works
Serres, F., & Carney, S. L. (2006) · Brain Research · doi:10.1016/j.brainres.2006.05.023 · Cited by 46 · see citing works
Studies on the interactions of tobacco leaf and tobacco smoke constituents and monoamine oxidase
Castagnoli, K., Steyn, S. J., Magnin, G., der Schyf, C. J. V., Fourie, I., Khalil, A. A., & Castagnoli, N. (2002) · Neurotoxicity Research · doi:10.1080/10298420290015854 · Cited by 46 · see citing works
Visanji, N. P., O’Neill, M. J., & Duty, S. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.04.015 · Cited by 45 · see citing works
Bitner, R. S., & Nikkel, A. L. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02485-x · Cited by 44 · see citing works
Pharmacological Enhancement of Neuronal Survival
Calabrese, E. J. (2008) · Critical Reviews in Toxicology · doi:10.1080/10408440801981973 · Cited by 44 · see citing works
Nicotinic receptors as targets for therapeutic discovery
Lippiello, P., Bencherif, M., Hauser, T. A., Jordan, K., Letchworth, S., & Mazurov, A. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.9.1185 · Cited by 43 · see citing works
Hijioka, M., Matsushita, H., Ishibashi, H., Hisatsune, A., Isohama, Y., & Katsuki, H. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.07.024 · Cited by 43 · see citing works
Novel Pharmacotherapies in Parkinson’s Disease
Tizabi, Y., Getachew, B., & Aschner, M. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00375-5 · Cited by 43 · see citing works
Unhealthy Behaviours and Risk of Parkinson’s Disease: A Mendelian Randomisation Study
Heilbron, K., Jensen, M. P., Bandrés‐Ciga, S., Fontanillas, P., Blauwendraat, C., Nalls, M. A., Singleton, A., Smith, G. D., Cannon, P., & Noyce, A. J. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202487 · Cited by 43 · see citing works
Plaza‐Zabala, A., Berrendero, F., Suárez, J., Bermúdez‐Silva, F. J., Fernández‐Espejo, E., Serrano, A., Pavón, F. J., Parsons, L. H., de Fonseca, F. R., Maldonado, R. J., et al. (2009) · Synapse · doi:10.1002/syn.20733 · Cited by 43 · see citing works
Belluardo, N., Olsson, P. A., Mudò, G., Sommer, W. H., Amato, G., & Fuxé, K. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.01.061 · Cited by 43 · see citing works
Bencherif, M. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.37 · Cited by 44 · see citing works
Lockman, P. R., der Schyf, C. J. V., Abbruscato, T. J., & Allen, D. D. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03162.x · Cited by 41 · see citing works
Abdin, M. J., Morioka, N., Morita, K., Kitayama, T., Kitayama, S., Nakashima, T., & Dohi, T. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.08.011 · Cited by 41 · see citing works
Ravikumar, R., Flora, G., Geddes, J. W., Hennig, B., & Toborek, M. J. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.02.018 · Cited by 41 · see citing works
A Placebo‐Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa‐Induced Dyskinesia
Trenkwalder, C., Berg, D., Rascol, O., Eggert, K. M., Ceballos-Baumann, A., Corvol, J., Storch, A., Zhang, L., Azulay, J., Broussolle, E., et al. (2016) · Movement Disorders · doi:10.1002/mds.26569 · Cited by 40 · see citing works
Microarray Technology and its Application on Nicotine Research
Li, M. D., Konu, Ö., Kane, J. K., & Becker, K. G. (2002) · Molecular Neurobiology · doi:10.1385/mn:25:3:265 · Cited by 38 · see citing works
Mouhape, C., Costa, G., Ferreira, M., Abin‐Carriquiry, J. A., Dajas, F., & Prunell, G. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9931-1 · Cited by 38 · see citing works
Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders
Quik, M., Boyd, J. T., Bordia, T., & Perez, X. A. (2018) · Nicotine & Tobacco Research · doi:10.1093/ntr/nty063 · Cited by 38 · see citing works
Riveles, K., Huang, L. Z., & Quik, M. (2008) · NeuroToxicology · doi:10.1016/j.neuro.2008.02.001 · Cited by 37 · see citing works
- Authors
- Ryan, R. E., Ross, S. A., Drago, J., & Loiacono, R. E.
- Affiliations
- Monash University (AU)
- Monash Medical Centre (AU)
- Corresponding author
- Ryan, R E
- ORCID
- Drago, J
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2001-04
- Volume
- 132
- Issue
- 8
- Pages
- 1650-1656
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC1572727
- OpenAlex
- W1993742630
- Cited by
- 188
- References
- 51
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 1 · 2023: 6 · 2022: 2 · 2021: 8 · 2020: 8 · 2019: 5 · 2018: 7 · 2017: 3 · 2016: 8 · 2015: 5 · 2014: 8 · 2013: 7 · 2012: 5
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Monash University
- University of Melbourne
- Medical Research Council
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Keywords
- nicotine, neuroprotection, 6-hydroxydopamine, methamphetamine, striatal dopaminergic neurons, Parkinson's disease, receptor desensitization, dose-dependent effects, knockout mice, neurodegeneration
- MeSH terms
- Animals, Dopamine, Dose-Response Relationship, Drug, Hydroxydopamines, Male, Methamphetamine, Nerve Endings, Nicotine, Receptors, Nicotinic, Sympathectomy, Chemical, Rats, Sprague-Dawley, Mice, Knockout, Neuroprotective Agents, Nicotinic Agonists, Dopamine Uptake Inhibitors, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
